source
- CAR-T biotech Caribou Biosciences halts two programs and seeks exit after funding shortfallCaribou Biosciences announced it is suspending two of its allogeneic CAR-T cell therapy projects. The company said it could not obtain the financing needed to keep the programs alive and is now lo…
- Venture capital continues to flow into biopharma in Q3 2026, favoring later-stage and AI-driven companiesVenture capital funding into biopharma topped $16 billion in the first half of 2026 and kept rising in the third quarter, according to industry sources. Investors remain selective, directing money…